Immunocore Holdings

Immunocore Holdings Plc operates as a holding company. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Earnings data Q4 2020

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to an 80.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See an 80% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?

Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Immunocore announce s c linical t rial c ollaboration with Sanofi to evaluate Sanofi's product candidate SAR 444 245 , non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma

Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi's product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma

Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

The latest geographic growth increases Medison's global footprint across 25 countries in four continents, further strengthening its commercial offering PETACH TIKVAH, Israel , May 23, 2022 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, today announced the addition of new markets to its multi-territorial agreement with Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease. The multi-territorial agreement to help seek regulatory authorization and commercialize Immunocore's KIMMTRAK® (tebentafusp -tebn) for the treatment of unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma that affects the eye, which covers Canada, twenty markets across Central Eastern Europe and Israel, will now extend to Australia and New Zealand.

Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand

Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update

Immunocore to present at the 21 st Annual Needham Healthcare Conference

Immunocore to present at the 21st Annual Needham Healthcare Conference

Legend Biotech

With trials aimed at increasing addressable markets in the coming years, Legend and Immunocore could reward investors.

2 Biotechs With Recent FDA Approvals to Hold for the Next Decade

European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

Axsome Therapeutics

GlaxoSmithKline

Looking for a healthcare stock with strong leadership? Our roundtable likes Immunocore, Axsome Therapeutics, and GlaxoSmithKline.

3 CEOs to Invest In

Immunocore Holdings PLC Sponsored ADR (IMCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Immunocore Holdings PLC Sponsored ADR (IMCR) Moves to Buy: Rationale Behind the Upgrade

The average of price targets set by Wall Street analysts indicates a potential upside of 134.8% in Immunocore Holdings PLC Sponsored ADR (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 135% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?

Immunocore to present at Oppenheimer's 32 nd Annual Healthcare Conference

Immunocore to present at Oppenheimer's 32nd Annual Healthcare Conference

Immunocore Reports Full Year 2021 Financial Results and Provides Business Update

Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

Immunocore to present at the SVB Leerink Global Healthcare Conference

The FDA has approved Immunocore Holdings plc (tebentafusp-tebn) for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).

FDA Approves First T Cell Receptor Therapy From Immunocore For Eye Cancer

Immunocore announces FDA approval of KIMMTRAK ® ( tebentafusp- tebn ) for the treatment of unresectable or metastatic uveal melanoma

Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma

Immunocore to present at the 40 th Annual J.P. Morgan Healthcare Conference

Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 6 December 2021) Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announces the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid tumors.

Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4

Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update

Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel

Immunocore announces publication of phase 3 data comparing tebentafusp with investigator's choice in The New England Journal of Medicine

Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial

News for Immunocore Holdings Stock (IMCR)